This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2017 Jul 15;390(10091):230.

doi: 10.1016/S0140-6736(17)31834-2.

Department of Error

No authors listed

PMID: 28721878
DOI: 10.1016/S0140-6736(17)31834-2

Published Erratum

Department of Error

No authors listed. Lancet. 2017.

. 2017 Jul 15;390(10091):230.

doi: 10.1016/S0140-6736(17)31834-2.

PMID: 28721878
DOI: 10.1016/S0140-6736(17)31834-2

No abstract available

PubMed Disclaimer

Erratum for

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaçi D, Nograles K, Mehta A, Cichanowitz N, Li Q, Liu K, La Rosa C, Green S, Kimball AB. Reich K, et al. Lancet. 2017 Jul 15;390(10091):276-288. doi: 10.1016/S0140-6736(17)31279-5. Epub 2017 Jun 6. Lancet. 2017. PMID: 28596043 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations